Michel P. Ducreux, MD, PhD

New agents/strategies on the horizon in bile duct cancer

07/10/2018

CIO 2022-33 Atezolizumab + Bevacizumab vs Sorafenib in HCC Patients With Prior Locoregional Therapy: IMbrave150 Exploratory Data

BEST POSTER WINNER Late-breaking abstract / Here, we report post hoc exploratory results of atezo + bev vs sorafenib (sor) in pts who had prior LRT using updated IMbrave150 data with 12 m...

Michel P. Ducreux , MD, PhD;

Sairy Hernandez ;

Amit G. Singal ;

Wendy Verret ;

Allan Nicholas , MD, FACC;

Riad Salem , MD, MBA;

Richard S. Finn ;

Peter R. Galle , MD, PhD;

Andrew Zhu ;

Philippe Merle ;

10/17/2022

Impact of molecular profiling on survival in patients with advanced biliary tract cancers

Biliary tract cancers (BTC) are a group of rare cancers (intrahepatic cholangiocarcinoma [ICC], extrahepatic cholangiocarcinoma [ECC], and gallbladder carcinoma [GBC]) that are epidemiolo...

P. Dartigues ;

M. Bani ;

C. Smolenschi ;

J. Scoazec ;

Michel P. Ducreux , MD, PhD;

D. Malka ;

L. Antoun ;

I. Deneche ;

A. Boileve ;

A. Tarabay ;

E. Rouleau ;

A. Hollebecque ;

E. El Rawadi ;

R. Eid ;

L. Lacroix ;

Marc Valery ;

V. Boige ;

06/25/2023

News and Current State of Research in Small Bowel Adenocarcinoma

Michel P. Ducreux, MD, PhD, presents his session "News and Current State of Research in Small Bowel Adenocarcinoma" at the World Congress on Gastrointestinal Cancer 2023.

Michel P. Ducreux , MD, PhD;

07/07/2023

Multidisciplinary Tumor Board: A Challenging Patient With Colorectal Cancer

Josep Tabernero , MD, PhD;

Thomas Gruenberger , MD;

Sharlene Gill , MD, MPH, MBA, FRCPC;

Michel P. Ducreux , MD, PhD;

Eric Van Cutsem , MD, PhD;

Axel Grothey , MD;

07/19/2019

What is new in anal cancer in the last 12 months?

Michel P. Ducreux , MD, PhD;